Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 26.08.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | faction Agreement and the matters disclosed under Item 5.02 below is attached hereto as Exhibit 99.1. The information se |
| 25.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers |
| 03.06.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Submission of Matters to a Vote of Security Holders. On May 28, 2025, Envoy Medical, Inc. (the “Co |
| 19.05.2025 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Offi |
| 11.06.2024 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; |
| 19.12.2023 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Inter |
| 20.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Co |
| 05.10.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | eport is incorporated herein by reference. Item 5.02 Departure of Directors or Certain Officers; Election of Directors |
| 03.04.2023 | Item 4.02 — Bilanzkorrekturen | EXTREM | SEC | Item 4.02. Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim R |
Stammdaten
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices; and Acclaim cochlear implants. Envoy Medical Corporation was formerly known as St. Croix Medical, Inc. and changed its name to Envoy Medical Corporation in December 2004. The company was founded in 1995 and is based in White Bear Lake, Minnesota.
Unternehmen & Branche
| Name | Envoy Medical, Inc. |
|---|---|
| Ticker | COCH |
| CIK | 0001840877 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Devices |
| SIC | 3842 · Orthopedic, Prosthetic & Surgical Appliances & Supplies |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 14,1 Mio. USD |
| Beta | 2,05 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 241,000 | -23,756,000 | -1.23 | 8,558,000 | -12,158,000 |
| 2025-09-30 | 10-Q | 42,000 | -6,482,000 | -0.35 | 8,181,000 | -7,661,000 |
| 2025-06-30 | 10-Q | 78,000 | -5,690,000 | -0.32 | 9,900,000 | -29,859,000 |
| 2025-03-31 | 10-Q | 46,000 | -4,998,000 | -0.29 | 10,385,000 | -24,224,000 |
| 2024-12-31 | 10-K | 225,000 | -20,795,000 | -1.49 | 11,538,000 | -18,842,000 |
| 2024-09-30 | 10-Q | 56,000 | -5,960,000 | -0.39 | 9,397,000 | -18,543,000 |
| 2024-06-30 | 10-Q | 68,000 | -3,947,000 | -0.29 | 6,737,000 | -12,401,000 |
| 2024-03-31 | 10-Q | 59,000 | -6,270,000 | -0.41 | 8,480,000 | -7,427,000 |
| 2023-12-31 | 10-K | 316,000 | -29,922,000 | -2.54 | 8,271,000 | -1,776,000 |
| 2023-09-30 | 10-Q | 80,000 | 1,563,000 | 0.13 | 23,601,000 | 4,786,000 |
| 2023-06-30 | 10-Q | 63,000 | -13,337,000 | -1.31 | 45,043,101 | -45,119,000 |
| 2023-03-31 | 10-Q | 78,000 | -13,253,000 | -1.31 | 45,921,288 | -47,495,000 |
| 2022-12-31 | 10-K | 237,000 | -15,923,000 | -1.57 | 2,556,000 | -36,195,000 |
| 2022-09-30 | 10-Q | 57,000 | -1,339,000 | -0.13 | 427,811,339 | -25,545,000 |
| 2022-09-30 | 10-K | 1,378,113 | ||||
| 2022-06-30 | 10-Q | -1,236,000 | 427,168,027 | -26,181,000 | ||
| 2022-03-31 | 10-Q | -1,871,000 | 426,337,892 | -25,588,000 | ||
| 2021-12-31 | 10-K | -251,633 | 426,903,621 | -44,960,000 | ||
| 2021-09-30 | 10-Q | 5,567,102 | 426,950,673 | -32,764,081 | ||
| 2021-06-30 | 10-Q | 371,144 | 427,829,210 | -38,331,183 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-02-12 | TAYLOR GLEN A | 10% Owner | Open Market Purchase | 18,750,000 | 0.40 | 7,500,000.00 | +997,1% | |
| 2026-02-12 | Patel Mona Chetan | Director | Open Market Purchase | 312,500 | 0.40 | 125,000.00 | +16,6% | |
| 2026-02-12 | Potashnick Robert | Officer, Interim CFO | Open Market Purchase | 212,500 | 0.40 | 85,000.00 | +11,3% | |
| 2026-02-12 | Kantor Susan | Director | Open Market Purchase | 96,150 | 0.40 | 38,460.00 | +5,1% | |
| 2026-02-12 | BRYNELSEN CHARLES | Director | Open Market Purchase | 1,000,000 | 0.40 | 400,000.00 | +53,2% | |
| 2026-02-12 | Lucas Brent T. | Director, Officer, Chief Executive Officer | Open Market Purchase | 62,500 | 0.40 | 25,000.00 | +3,3% | |
| 2025-06-11 | Patel Mona Chetan | Director | Open Market Purchase | 2,500 | 1.47 | 3,675.00 | +0,5% | |
| 2025-06-06 | Patel Mona Chetan | Director | Open Market Purchase | 10,000 | 1.46 | 14,600.00 | +1,9% | |
| 2025-05-27 | BRYNELSEN CHARLES | Director | Open Market Purchase | 35,000 | 1.65 | 57,673.00 | +7,7% | |
| 2025-05-23 | BRYNELSEN CHARLES | Director | Open Market Purchase | 13,000 | 1.64 | 21,362.90 | +2,8% | |
| 2025-05-22 | BRYNELSEN CHARLES | Director | Open Market Purchase | 2,000 | 1.68 | 3,366.80 | +0,4% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.